KOL selection, speaker bureau, and clinical investigator diligence.
A KOL identification platform tells you who is publishing in your therapeutic area. It does not tell you that a candidate has been excluded from federal health programs, that a state medical board has an open investigation, or that the candidate's CMS Open Payments record is concentrated with a competitor. The Physician Vetting Report fills that gap. NPI-anchored, defamation-guarded, federal-records-first.
Why pharmaceutical KOL and investigator diligence is harder than it looks
A medical affairs team building a KOL panel for a new molecule in a specific therapeutic area starts with the obvious sources: a KOL identification platform pulls from PubMed citation count and h-index. A commercial team layers in conference faculty rosters, patient advocacy board memberships, and prescription volume from claims data. The names converge into a candidate list that looks well-researched on the slide deck.
What the slide deck does not show is the verification layer. Is the candidate currently licensed in the state where the speaker program will run? Is the candidate's ABMS certification still active in the specialty being engaged? Has the candidate been added to the OIG LEIE federal exclusion list since the candidate's last engagement? Is there a state medical board investigation that is open but not yet adjudicated? Has the candidate's CMS Open Payments pattern shifted toward a competitor in the past two years? These are the questions a compliance officer raises during contract review, and they are the questions a medical affairs team would prefer to answer before the candidate is contracted, not after.
The diligence problem is multiplied for clinical operations teams selecting investigators for a Phase II or Phase III trial. The site-selection brief covers the prior trial history, the NIH grant record, the publication depth in the indication, and the institutional research infrastructure. What can fall through is the public-record check: federal exclusion, state board active, ABMS certification matched against the trial therapeutic area, ACGME training pedigree at the program named on the bio. A wrong-investigator headache discovered after enrollment is one of the more expensive corrective actions in clinical operations.
The hardest part is that no single existing platform covers the full vetting surface. The KOL identification platforms cover scientific influence; the existing aggregate spend systems cover transparency reporting; the credentialing vendors cover hospital-employed providers but rarely the academic-medical-center KOLs the medical affairs team is recruiting. The Physician Vetting Report is the layer that pulls federal-and-state public records into one document, anchored to the NPI, with the citation discipline a compliance officer can defend.
What MentionFox brings to a pharmaceutical workflow
The Physician Vetter is the workhorse for KOL, speaker bureau, advisory board, and investigator diligence. The methodology pages explain exactly which sources are used and how each is weighted. The supporting subject-type methodologies cover dentistry, behavioral health, and pharmacy when the engagement extends beyond physician HCPs.
Physician Vetter
The flagship report. Twelve sections in the full report, NPI-anchored, every claim cited. For pharmaceutical use, the highest-value sections are the License and Disciplinary History anchored to the OIG LEIE and state board records, the CMS Open Payments breakdown by category over the most recent reporting years, the Specialty Certification check against ABMS or ABPN matching the therapeutic area, the Publication and Research Record from PubMed and NIH RePORTER, and the Comparable Physicians cohort that contextualizes the candidate against archetype-matched peers in the same specialty and career stage. Snapshot at 10 credits, full report at 50 credits.
Physician Methodology
The document medical affairs and compliance leadership read once before standardizing the report into the candidate dossier flow. Covers the four-class source taxonomy, the disambiguation hard-gate that prevents wrong-person reports, the defamation guardrails on the malpractice surface, the UK Professional Head of Intelligence Assessment Probability Yardstick used for confidence statements, and the explicit limits of public-record physician verification. The basis on which a pharmaceutical compliance officer can integrate the report into the medical affairs SOP.
Verification Vetter Methodology
The trust spine. Explains the source-class taxonomy that runs through every report on the platform — Federal-Primary, Authoritative-Secondary, Aggregator, Unverified — the citation discipline, the defamation logic, and the disambiguation hard-gate. Useful when a pharmaceutical compliance officer needs to validate the methodology with internal legal before integrating the reports into the standard candidate-vetting workflow.
Dentist Methodology
For dental and oral health programs. Covers state dental boards, ADA-recognized specialty boards including the American Board of Periodontology and the American Board of Oral and Maxillofacial Surgery, DEA registration, and the federal OIG exclusion list. Useful for medical affairs teams supporting dental device, oral care, and dental therapeutics programs that engage dentist KOLs.
Therapist Methodology
For mental health and behavioral health programs. Covers state licensing boards across all fifty states, the Association of Social Work Boards records, the American Board of Professional Psychology certification status, modality-specific certifying bodies, and the OIG LEIE applied to mental health providers. Useful for psychiatric pharmaceutical programs where the engagement extends to psychologists, social workers, and licensed counselors alongside psychiatrist KOLs.
Pharmacist Methodology
For specialty-pharmacy and compounding-pharmacy partner diligence. Covers state pharmacy boards, the National Association of Boards of Pharmacy records, the Pharmacy Compounding Accreditation Board where the pharmacy compounds, DEA registration, and the federal OIG exclusion list. Useful for pharmaceutical commercial teams establishing specialty pharmacy distribution arrangements or launching a 503A or 503B compounded therapeutic.
A typical workflow — what a medical affairs lead actually does
A medical affairs lead at a mid-size pharmaceutical company is building a national KOL panel for a Phase III readout in a rare-disease indication. The KOL identification platform has surfaced sixty candidates by publication count and citation depth in the indication. Commercial has layered on conference-faculty roster matches and prescription-volume signal from claims data. The list is now thirty-two names, ranked by an internal composite.
Before contracting any of the top fifteen, the medical affairs lead runs the Physician Snapshot across all thirty-two candidates for 320 credits. Twenty-eight clear cleanly: federal exclusion clean, state licensure active, ABMS certification active in the relevant specialty, no concerning public-reputation flags. Four return flags. One has a state medical board active investigation in their primary state — the medical affairs lead removes the candidate from the panel entirely. One has a CMS Open Payments record concentrated with a direct competitor over the past two years — flagged for commercial review and ultimately deferred. Two have older state board record-keeping orders that have been resolved — flagged for compliance review and kept on the candidate list with documentation in the candidate dossier.
For the top ten finalists, the medical affairs lead upgrades each to a full Physician Vetting Report for 500 additional credits. The full reports go into the candidate dossiers alongside the KOL identification platform export, the prescription-volume claims-data summary, and the standard contracting materials. The Comparable Physicians section in each full report is particularly useful: the medical affairs lead uses the cohort to argue panel composition diversity to the commercial leadership review.
Total spend: 820 credits. Total time saved versus the previous diligence process which involved a partial-coverage compliance vendor and a manual public-record sweep: roughly two weeks of medical affairs analyst time on the panel, plus the avoided downstream cost of contracting a candidate whose state board investigation would have surfaced post-engagement.
What data sources the report draws from
Every claim in the Physician Vetting Report cites a named, public, federal-or-state source. For pharmaceutical KOL and investigator diligence, these are the sources that drive the analysis.
- CMS NPI Registry — the National Provider Identifier database from the Centers for Medicare and Medicaid Services. Canonical identity anchor that prevents wrong-person reports across candidates with similar names.
- OIG LEIE — the Office of Inspector General List of Excluded Individuals and Entities. Federal exclusion list. A positive match is dispositive for any pharmaceutical engagement, given the company's federal contracting and reimbursement exposure.
- FDA debarment list — surfaced as part of the disciplinary check where applicable to clinical investigator diligence.
- State medical boards — fifty state boards plus the District of Columbia. Licensure status, disciplinary actions, and current investigations. The lookup URL is surfaced directly for verification of record.
- ABMS — the American Board of Medical Specialties and its twenty-four member boards. Specialty certification status across the candidate's listed specialties, matched against the therapeutic area being engaged.
- ABPN — the American Board of Psychiatry and Neurology. Subspecialty certification for psychiatric and neurological therapeutic areas.
- ACGME — the Accreditation Council for Graduate Medical Education. Verifies residency and fellowship training program accreditation, which validates the training-pedigree claims a KOL candidate makes on their bio page or a clinical investigator brings to the site-selection brief.
- CMS Open Payments — the Sunshine Act database. Total payments by category over the most recent reporting years, broken out by manufacturer where the report scope warrants. Critical for KOL panel composition and competitive-relationship awareness.
- PubMed and NIH iCite — publication record, h-index proxy, recent publication velocity in the indication.
- NIH RePORTER — NIH grant history. Indicates research productivity and federal-research relationship.
- ClinicalTrials.gov — federal clinical trial registry. Investigator history surfaces where the candidate is named on prior trial registrations.
- CourtListener — federal and state court docket aggregator. Civil malpractice case search by name and specialty. Framed as litigation activity, not adjudicated wrongdoing. Strong defamation guardrails apply.
Sample report walkthrough
The canonical sample on file is Anthony Stephen Fauci, former director of the National Institute of Allergy and Infectious Diseases. The full Physician Vetting Report covers his federal physician-scientist career arc, NIH grant record from RePORTER, publication depth from PubMed, ClinicalTrials.gov investigator history, and post-retirement public-reputation pattern. Federal-Primary sources only.
For an at-onboarding Snapshot example for a current-practice surgeon-author KOL, see the Atul Gawande Snapshot. For a non-academic emergency-medicine Snapshot, see the Jocko R. Zifferblatt sample. For a pharmacist sample relevant to specialty pharmacy diligence, see the Jonathan Edward Smith Snapshot.
Pricing for this use case
Physician Snapshot — for KOL panel and speaker bureau onboarding
10 credits. Returns in roughly sixty seconds. NPI verified, OIG LEIE clean or flagged, state board lookup URL with current status, ABMS or ABPN cert status matched against the relevant specialty, top public-reputation flags. The right tier for the at-scale screen across a candidate panel where most candidates will pass cleanly.
Physician Vetting Report — for finalists and clinical investigators
50 credits. Returns in three to five minutes. All twelve sections, 1,800-3,500 words. Full disciplinary surface, Open Payments breakdown by category over the most recent reporting years, publication and grant record, ClinicalTrials.gov investigator history, ACGME training pedigree, comparable-physician cohort, full source citations. The tier medical affairs and clinical operations attach to the candidate dossier.
Credit packs and enterprise volume arrangements are available. See the full pricing page for credit-pack options.
Mini case studies
The mid-size pharma rare-disease KOL panel build
Thirty-two candidates surfaced by the KOL identification platform and prescription-volume claims data. Snapshot batch run for 320 credits. Twenty-eight cleared. Four flagged: one state board investigation removed from panel, one competitor-concentrated Open Payments pattern deferred for commercial review, two resolved older state board record-keeping orders kept with documentation. Top ten finalists upgraded to full reports for 500 credits. Total: 820 credits. Avoided downstream cost: roughly two weeks of analyst time and the contracting cost of one candidate that would have surfaced a state board issue post-engagement.
The clinical operations Phase III site-selection screen
Eighteen candidate principal investigators across fourteen academic and community sites for a Phase III oncology trial. The clinical operations lead ran full Physician Vetting Reports across all eighteen for 900 credits before the site-feasibility visits. The reports surfaced one candidate with thin ABMS certification in the trial-relevant subspecialty — the candidate was reassigned to a sub-investigator role under a more specialty-appropriate principal investigator at the same site. The change saved a feasibility-visit cycle and a downstream protocol amendment. The clinical operations lead standardized full reports into the site-selection SOP thereafter.
Frequently asked questions
Is this PhRMA Code compliant?
The data the report draws from is public-record provider data — federal records like the NPI Registry, OIG LEIE, and CMS Open Payments, plus state medical board licensure and ABMS certification. PhRMA Code on Interactions with Healthcare Professionals does not restrict the use of public-record vetting data to inform KOL or speaker bureau selection. Compliance with the PhRMA Code, the AdvaMed Code of Ethics, and individual company SOPs is the responsibility of the medical affairs and compliance teams reviewing the report.
What is CMS Open Payments and why does it matter for KOL diligence?
CMS Open Payments is the federal database mandated by the Sunshine Act tracking payments from pharmaceutical and medical-device manufacturers to physicians. For KOL diligence, the Open Payments record reveals the candidate's existing manufacturer relationships, including payment categories — research, consulting, food and beverage, travel, royalty — over the most recent reporting years. A concentrated payment pattern from a competitor or a spread across the relevant therapeutic area changes how the candidate fits into a medical affairs strategy.
How do you handle clinical investigator diligence?
The full Physician Vetting Report covers the dimensions a clinical operations site-selection team needs: NPI-anchored identity, ABMS specialty certification matched against the trial therapeutic area, ACGME-accredited training pedigree, PubMed publication record in the relevant indication, NIH RePORTER grant history, ClinicalTrials.gov investigator history where the investigator is named on prior trial registrations, and the OIG LEIE federal exclusion check. The report does not query the FDA Bioresearch Monitoring program directly because that data is not fully public, but it surfaces FDA debarment list status as part of the disciplinary check.
Can we use this for speaker bureau onboarding?
Yes. The Physician Snapshot at 10 credits is the right tier for at-onboarding screening of speaker bureau candidates. It surfaces the federal exclusion check, state board licensure, ABMS or ABPN certification, and the CMS Open Payments pattern. The full report is the right tier for top-tier KOL candidates where the medical affairs team needs publication depth and the comparable-physician cohort to assess fit relative to other candidates in the therapeutic area.
What about HCP transparency reporting?
Existing reports do not generate transparency reports. They surface the existing CMS Open Payments record so a medical affairs team understands the payment landscape around a candidate before engaging. The transparency reporting obligations of the engaging company are handled by the company's existing aggregate spend system.
How does this fit alongside our existing KOL identification platforms?
Existing KOL platforms identify candidates by publication volume, citation count, social influence, and conference presence. The Physician Vetting Report adds the verification layer — federal exclusion clean, state licensure active, ABMS certification in the relevant specialty, ACGME training pedigree validated — that the identification platforms generally do not surface.
Do you cover dentistry, dental device, and oral health KOLs?
Yes via the Dentist methodology, which covers state dental boards, the ADA-recognized specialty boards, DEA registration where applicable, and the federal OIG exclusion list. The same federal-records-first approach applies to oral and maxillofacial surgery and prosthodontics specialties relevant to dental device and oral health programs.
Can the report be folded into our medical affairs SOP?
Yes. Each report cites every URL it draws from. Reports are reproducible — the same NPI, the same date, the same sources — so they integrate cleanly into a medical affairs candidate dossier or a clinical operations site-selection file. The methodology page is the document that medical affairs and compliance leadership read once before integrating reports into the SOP.